GlassScriptPhysician profile
Todd David Baca
NPI 1720763451
$1,428.27
in general payments reported to CMS, 2019-2025
18 companies · $679 in 2025
The $679 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $750 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $184.65 | 2024 | Injectafer |
| Abbvie INC. | $176.05 | 2024-2025 | |
| Medtronic, INC. | $172.37 | 2024 | Micra |
| Lilly USA, LLC | $125.75 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $120.14 | 2024-2025 | Shingrix, Arexvy, Bexsero |
| Actelion Pharmaceuticals US, INC. | $101.32 | 2025 | Opsumit, Uptravi |
| Exact Sciences Corporation | $92.81 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $78.18 | 2024-2025 | |
| Antares Pharma, INC. | $73.06 | 2024-2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.74 | 2024-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $66.92 | 2024-2025 | Breztri |
| Tolmar, INC. | $49.45 | 2025 | Jatenzo |
| Novo Nordisk INC | $27.65 | 2025 | Ozempic, Rybelsus |
| Hologic Sales and Service, LLC | $20.22 | 2024 | Aptima |
| Novartis Pharmaceuticals Corporation | $18.05 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $17.95 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Dexcom, INC. | $17.25 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $15.71 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Baca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.